Athenex Dirección

Dirección controles de criterios 3/4

El CEO de Athenex's es Johnson Lau , nombrado en Jan 2011, tiene una permanencia de 12.33 años. compensación anual total es $714.51K, compuesta por 73.5% salario y 26.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.99% de las acciones de la empresa, por valor de €271.68K. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 4.5 años, respectivamente.

Información clave

Johnson Lau

Chief Executive Officer (CEO)

US$714.5k

Compensación total

Porcentaje del salario del CEO	73.5%
Permanencia del CEO	12.3yrs
Participación del CEO	3.0%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	4.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Johnson Lau en comparación con los beneficios de Athenex?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	US$715k	US$525k	-US$98m
Sep 30 2022	n/a	n/a	-US$178m
Jun 30 2022	n/a	n/a	-US$192m
Mar 31 2022	n/a	n/a	-US$198m
Dec 31 2021	US$2m	US$525k	-US$158m
Sep 30 2021	n/a	n/a	-US$132m
Jun 30 2021	n/a	n/a	-US$135m
Mar 31 2021	n/a	n/a	-US$144m
Dec 31 2020	US$3m	US$161k	-US$142m
Sep 30 2020	n/a	n/a	-US$118m
Jun 30 2020	n/a	n/a	-US$116m
Mar 31 2020	n/a	n/a	-US$108m
Dec 31 2019	US$4m	US$519k	-US$123m
Sep 30 2019	n/a	n/a	-US$129m
Jun 30 2019	n/a	n/a	-US$141m
Mar 31 2019	n/a	n/a	-US$145m
Dec 31 2018	US$3m	US$500k	-US$117m
Sep 30 2018	n/a	n/a	-US$119m
Jun 30 2018	n/a	n/a	-US$96m
Mar 31 2018	n/a	n/a	-US$97m
Dec 31 2017	US$5m	US$500k	-US$131m
Sep 30 2017	n/a	n/a	-US$143m
Jun 30 2017	n/a	n/a	-US$144m
Mar 31 2017	n/a	n/a	-US$118m
Dec 31 2016	US$522k	US$200k	-US$88m

Compensación vs. Mercado: La compensación total de Johnson($USD714.51K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Johnson ha sido consistente con los resultados de la empresa en el último año.

CEO

Johnson Lau (62 yo)

12.3yrs

Permanencia

US$714,505

Compensación

Dr. Yiu-Nam Lau, also known as Johnson, MBBS, MD, FRCP, Ph D., has been the Chief Executive Officer of Athenex, Inc. since 2011. Dr. Lau is the Vice Chairman and CEO of Axis Therapeutics.Dr. Lau serves as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yiu-Nam Lau	Chairman & CEO	12.3yrs	US$714.51k	2.99% $ 271.7k
Jeffrey Yordon	COO & President of Athenex Pharmaceutical Division	6.3yrs	US$524.66k	0.14% $ 12.9k
Daniel Lang	President of Athenex Cell Therapy	2yrs	US$481.15k	0.047% $ 4.3k
Allen Barnett	Co-Founder & President Emeritus	12.3yrs	sin datos	sin datos
Joe Annoni	Chief Financial Officer	1.3yrs	sin datos	0.0043% $ 394.0
Steven Adams	Chief Accounting Officer	1.8yrs	US$289.28k	0.0018% $ 163.8
Caileigh Dougherty	Director of Investor Relations	no data	sin datos	sin datos
Jacqueline Li	Vice President of Alliance Management & Corporate Development	3.3yrs	sin datos	sin datos
John Matthei	Chief Human Resource Officer	no data	sin datos	sin datos
David Cutler	Deputy Chief Medical Officer of Biologics & Cell Therapy	3.3yrs	sin datos	sin datos
Timothy Cook	Chief Business & Commercial Officer of Proprietary Drugs	4.8yrs	sin datos	0.048% $ 4.3k
Darrel Cohen	Chief Medical Officer of Cell Therapy	less than a year	sin datos	sin datos

3.3yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2MT0 se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yiu-Nam Lau	Chairman & CEO	19.5yrs	US$714.51k	2.99% $ 271.7k
John Vierling	Independent Director	4.1yrs	US$42.00k	0.14% $ 12.9k
Jinn Wu	Independent Director	16.1yrs	US$40.86k	0.40% $ 36.6k
Robert Jay Spiegel	Independent Director	2.8yrs	US$46.00k	0.053% $ 4.8k
Kwan-Hung Tsang	Independent Director	4.8yrs	US$55.14k	0.20% $ 17.8k
Jordan Kanfer	Independent Director	4.1yrs	US$42.00k	0.0099% $ 898.2
Manson Fok	Director	7.9yrs	US$35.71k	1.28% $ 116.3k
Stephanie Davis	Lead Independent Director	4.1yrs	US$46.00k	0.093% $ 8.4k

4.5yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2MT0 se considera experimentada (4.5 años de antigüedad promedio).

Athenex Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Insufficient new directors

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Insufficient new directors

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Insufficient new directors

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021)

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021)

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought €54k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought €136k worth of stock

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Insider recently sold €1.6m worth of stock

Independent Director recently sold €385k worth of stock

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)

New 90-day low: €4.52

Revenue beats expectations

Athenex, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Athenex, Inc. Enters into Second Amendment to the License Agreement

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

New 90-day high: €11.80

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

New 90-day low: €9.45

Athenex, Inc. Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer

Revenue beats expectations

Third quarter 2020 earnings released: US$0.44 loss per share

Athenex, Inc. Announces FDA Allowance of IND Application for TCRT-ESO-A2, a TCR-T Cell Therapy

Independent Director recently bought €188k worth of stock

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $110 million.

New 90-day high - €12.20

New 90-day low - €8.85

Athenex, Inc. to Report Q2, 2020 Results on Aug 06, 2020